Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 8Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 2Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

fludarabine phosphate 16Peripheral Blood Stem Cell Transplantation 14Cytarabine 12Cyclophosphamide 12Whole-Body Irradiation 10Filgrastim 9Cyclosporine 9Busulfan 9Mycophenolic Acid 8Tacrolimus 7Etoposide 7Antilymphocyte Serum 7Radiotherapy 6Methotrexate 6Granulocyte Colony-Stimulating Factor 6Cord Blood Stem Cell Transplantation 6Methylprednisolone 5Flow Cytometry 5Thiotepa 4Mitoxantrone 4Melphalan 4Idarubicin 4Decitabine 4fludarabine 3aldesleukin 3Transplantation 3Interleukin-2 3Bortezomib 3Alemtuzumab 3Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Congenital Abnormalities × tipifarnib × Clear all
NCT00124644 2013-05-03

Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
30 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡